4 assets in Pancytopenia Due To IKZF1 Mutations

Therapeutic assets addressing Pancytopenia Due To IKZF1 Mutations, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Blinatumomab Pancytopenia Due To IKZF1 Mutations	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Olverembatinib Pancytopenia Due To IKZF1 Mutations	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Prednisone Pancytopenia Due To IKZF1 Mutations	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Tucidinostat Pancytopenia Due To IKZF1 Mutations	Nanfang Hospital, Southern Medical University	P2	CCC (53)